Page 1 | Search Results | Blood | American Society of Hematology

1-9 of 9

Sort by

Sort Order Select

Journal Articles

Addition of All-Trans Retinoic Acid (ATRA) to the Combination of Fludarabine, Cytarabine, Idarubicin, with or without GCSF in Older, Higher Risk Patients with AML and High-Risk MDS Does Not Improve the Outcome in Those with NPM1 Mutation.

Aziz Nazha, Carlos E. Bueso-Ramos, MD, PhD, Stefan Faderl, MD, Elihu H. Estey, MD, Susan M. O'Brien, Michael Farnandez, Martin Nguyen, Charles Koller, MD, Emil Freireich, MD, Miloslav Beran, Sherry Pierce, Jorge E. Cortes, MD, Hagop M. Kantarjian, MD, Farhad Ravandi, MD

Blood (2012) 120 (21): 2616.

https://doi.org/10.1182/blood.V120.21.2616.2616

Published: 2012

Journal Articles

Outcomes of Patients with Newly-Diagnosed Acute Myeloid Leukemia Over the Last 5 Decades At M.D. Anderson Cancer Center

Alfonso Quintás-Cardama, MD, Hagop Kantarjian, Farhad Ravandi, MBBS, Guillermo Garcia-Manero, Stefan Faderl, MD, Pierce Sherry, Mark Brandt, Gautam Borthakur, Michael Keating, MD, Emil Freireich, Jorge E Cortes

Blood (2011) 118 (21): 2606.

https://doi.org/10.1182/blood.V118.21.2606.2606

Published: 2011

Journal Articles

Late Relapses in Acute Myelogenous Leukemia: Analysis of Characteristics and Outcome.

Dushyant Verma, MD, FACP, Stefan Faderl, MD, Susan O’Brien, MD, Sherry Pierce, Jorge Cortes, MD, Khanh Vu, MD, Emil Freireich, MD, Michael J. Keating, MBBS, Hagop M. Kantarjian, MD, Farhad Ravandi, MBBS

Blood (2008) 112 (11): 951.

https://doi.org/10.1182/blood.V112.11.951.951

Published: 2008

Journal Articles

Relaxing the Protected Environment Has Not Adversely Impacted Early Outcome of Older Patients (≥ 50 years) with AML and HR- MDS Receiving Induction Therapy

Gloria Mattiuzzi, MD, Edythe Greenberg, RN, Sherry Pierce, RN, Jorge Cortes, MD, Emil Freireich, MD, Susan O’Brien, MD, Hagop Kantarjian, MD

Blood (2008) 112 (11): 3988.

https://doi.org/10.1182/blood.V112.11.3988.3988

Published: 2008

Journal Articles

Relative increase in leukemia-specific DNA in peripheral blood plasma from patients with acute myeloid leukemia and myelodysplasia

Anna Rogers, Youngson Joe, Taghi Manshouri, Amanda Dey, Iman Jilani, Francis Giles, Elihu Estey, Emil Freireich, Michael Keating, Hagop Kantarjian, Maher Albitar

Blood (2004) 103 (7): 2799–2801.

https://doi.org/10.1182/blood-2003-06-1840

Published: 2004

Journal Articles

Angiogenesis in acute and chronic leukemias and myelodysplastic syndromes

Alvaro Aguayo, Hagop Kantarjian, Taghi Manshouri, Cristi Gidel, Elihu Estey, Deborah Thomas, Charles Koller, Zeev Estrov, Susan O'Brien, Michael Keating, Emil Freireich, Maher Albitar

Blood (2000) 96 (6): 2240–2245.

https://doi.org/10.1182/blood.V96.6.2240

Published: 2000

Journal Articles

Sequential Homoharringtonine and Interferon- in the Treatment of Early Chronic Phase Chronic Myelogenous Leukemia

Susan O’Brien, Hagop Kantarjian, Charles Koller, Eric Feldman, Miloslav Beran, Michael Andreeff, Sergio Giralt, Bruce Cheson, Michael Keating, Emil Freireich, Mary Beth Rios, Moshe Talpaz

Blood (1999) 93 (12): 4149–4153.

https://doi.org/10.1182/blood.V93.12.4149

Published: 1999

Journal Articles

Randomized Phase II Study of Fludarabine + Cytosine Arabinoside + Idarubicin ± All-Trans Retinoic Acid ± Granulocyte Colony-Stimulating Factor in Poor Prognosis Newly Diagnosed Acute Myeloid Leukemia and Myelodysplastic Syndrome

Elihu H. Estey, Peter F. Thall, Sherry Pierce, Jorge Cortes, Miloslav Beran, Hagop Kantarjian, Michael J. Keating, Michael Andreeff, Emil Freireich

Blood (1999) 93 (8): 2478–2484.

https://doi.org/10.1182/blood.V93.8.2478

Published: 1999

Journal Articles

Implications of Potential Cure in Acute Myelogenous Leukemia: Development of Subsequent Cancer and Return to Work

Marcos de Lima, Sara S. Strom, Michael Keating, Hagop Kantarjian, Sherry Pierce, Susan O'Brien, Emil Freireich, Elihu Estey

Blood (1997) 90 (12): 4719–4724.

https://doi.org/10.1182/blood.V90.12.4719

Published: 1997

NARROW

Addition of All-Trans Retinoic Acid (ATRA) to the Combination of Fludarabine, Cytarabine, Idarubicin, with or without GCSF in Older, Higher Risk Patients with AML and High-Risk MDS Does Not Improve the Outcome in Those with NPM1 Mutation.

Outcomes of Patients with Newly-Diagnosed Acute Myeloid Leukemia Over the Last 5 Decades At M.D. Anderson Cancer Center

Late Relapses in Acute Myelogenous Leukemia: Analysis of Characteristics and Outcome.

Relaxing the Protected Environment Has Not Adversely Impacted Early Outcome of Older Patients (≥ 50 years) with AML and HR- MDS Receiving Induction Therapy

Relative increase in leukemia-specific DNA in peripheral blood plasma from patients with acute myeloid leukemia and myelodysplasia

Angiogenesis in acute and chronic leukemias and myelodysplastic syndromes

Sequential Homoharringtonine and Interferon- in the Treatment of Early Chronic Phase Chronic Myelogenous Leukemia

Randomized Phase II Study of Fludarabine + Cytosine Arabinoside + Idarubicin ± All-Trans Retinoic Acid ± Granulocyte Colony-Stimulating Factor in Poor Prognosis Newly Diagnosed Acute Myeloid Leukemia and Myelodysplastic Syndrome

Implications of Potential Cure in Acute Myelogenous Leukemia: Development of Subsequent Cancer and Return to Work

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only